<DOC>
	<DOCNO>NCT00771927</DOCNO>
	<brief_summary>SP942 non-interventional post-authorization safety study ( PASS ) evaluate long-term safety tolerability Vimpat® ( Lacosamide , LCM ) add-on treatment patient Epilepsy 16 year old partial-onset seizure uncontrolled current therapy . Using reported adverse event , incidence certain cardiovascular psychiatric event evaluate .</brief_summary>
	<brief_title>Post-Authorization Safety Study Assess Safety Vimpat add-on Therapy Patients With Partial-onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>This study include subject 16 year old Epilepsy diagnosis PartialOnset Seizures ; whose Seizure activity uncontrolled current therapy Patients prescribed Vimpat addon Antiepileptic Drug ( AED ) may include study The initiation addon AED therapy 2 day patient 's start study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Vimpat®</keyword>
	<keyword>Lacosamide</keyword>
	<keyword>LCM</keyword>
	<keyword>epilepsy</keyword>
	<keyword>epilepsy</keyword>
	<keyword>seizure</keyword>
	<keyword>partial seizure</keyword>
	<keyword>partial onset</keyword>
	<keyword>seizure disorder</keyword>
	<keyword>single seizure</keyword>
	<keyword>motor seizure</keyword>
	<keyword>convulsion</keyword>
	<keyword>add-on</keyword>
	<keyword>AED</keyword>
	<keyword>anti-epileptic</keyword>
	<keyword>anti-epileptic drug</keyword>
	<keyword>seizure control</keyword>
	<keyword>open-label</keyword>
	<keyword>post authorization</keyword>
	<keyword>PASS</keyword>
	<keyword>late stage</keyword>
	<keyword>trial</keyword>
	<keyword>study</keyword>
	<keyword>phase 4</keyword>
	<keyword>phase IV</keyword>
</DOC>